Elanco Animal Health Incorporated (ELAN)
- Previous Close
16.89 - Open
16.82 - Bid 17.02 x 1800
- Ask 17.04 x 1100
- Day's Range
16.56 - 17.09 - 52 Week Range
7.88 - 17.23 - Volume
2,767,500 - Avg. Volume
4,353,496 - Market Cap (intraday)
8.446B - Beta (5Y Monthly) 1.30
- PE Ratio (TTM)
-- - EPS (TTM)
-2.50 - Earnings Date Aug 5, 2024 - Aug 9, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
18.11
Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands. The company sells its products to third-party distributors; veterinarians; and farm animal producers, including beef and dairy farmers, as well as pork, poultry, and aquaculture operations. Elanco Animal Health Incorporated was founded in 1954 and is headquartered in Greenfield, Indiana.
www.elanco.com9,300
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: ELAN
Performance Overview: ELAN
Trailing total returns as of 5/9/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ELAN
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ELAN
Valuation Measures
Market Cap
8.35B
Enterprise Value
13.77B
Trailing P/E
--
Forward P/E
17.79
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
1.88
Price/Book (mrq)
1.34
Enterprise Value/Revenue
3.12
Enterprise Value/EBITDA
-61.47
Financial Highlights
Profitability and Income Statement
Profit Margin
-27.87%
Return on Assets (ttm)
1.39%
Return on Equity (ttm)
-18.22%
Revenue (ttm)
4.42B
Net Income Avi to Common (ttm)
-1.23B
Diluted EPS (ttm)
-2.50
Balance Sheet and Cash Flow
Total Cash (mrq)
352M
Total Debt/Equity (mrq)
95.07%
Levered Free Cash Flow (ttm)
388M
Research Analysis: ELAN
Company Insights: ELAN
ELAN does not have Company Insights